민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트
    11.
    发明公开
    민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트 有权
    用于预测敏感性皮肤和测试套件的生物标记

    公开(公告)号:KR1020140123033A

    公开(公告)日:2014-10-21

    申请号:KR1020140124117

    申请日:2014-09-18

    CPC classification number: C12Q1/6844 C12Q1/6813

    Abstract: Disclosed is a biomarker of which gene expression levels are specifically increased or reduced for sensitive skin. The biomarker specific to sensitive skin is used in such a diagnostic kit for sensitive skin and a screening method of an abirritant. The biomarker for diagnosis of sensitive skin according to the present invention contains one or more gene selected from a group consisting of HLA-C, TCEA1, IGHA1, TFRC, S100A8, LOC652128, SERPINB13, EHF, FLJ10781, TP63, CDH1, TNFRSF19, GM2A, FKBP5, PI3, PSPH, HORMAD1, SPRR2G, and ACTR2 or a group consiting of KBTBD10, TTN, ACTA1, MYBPC1, MB, MYOZ1, TPM1, CA3, CASQ1, ENO3, RBP4, GYG2, PPP1R1A, PYGM, G0S2, NEB, H19, LIPE, PLIN, H19, GPAM, FABP4, CIDEC, LPL, PCK1, ADIPOQ, PDE3B, ACVR1C, LPL, FABP4, DKFZP761N09121, TNMD, ATP6V1B1, C8orf22, and CRISP3.

    Abstract translation: 公开了一种生物标志物,其敏感性皮肤基因表达水平被特异地增加或降低。 敏感皮肤特异性的生物标志物用于敏感皮肤的诊断试剂盒和刺激物的筛选方法。 根据本发明的敏感性皮肤诊断用生物标志物含有选自HLA-C,TCEA1,IGHA1,TFRC,S100A8,LOC652128,SERPINB13,EHF,FLJ10781,TP63,CDH1,TNFRSF19,GM2A ,FKBP5,PI3,PSPH,HORMAD1,SPRR2G和ACTR2或KBTBD10,TTN,ACTA1,MYBPC1,MB,MYOZ1,TPM1,CA3,CASQ1,ENO3,RBP4,GYG2,PPP1R1A,PYGM,G0S2,NEB, H19,LIPE,PLIN,H19,GPAM,FABP4,CIDEC,LPL,PCK1,ADIPOQ,PDE3B,ACVR1C,LPL,FABP4,DKFZP761N09121,TNMD,ATP6V1B1,C8orf22和CRISP3。

    민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트
    12.
    发明公开
    민감성 피부 진단용 바이오 마커 및 이를 이용한 진단 키트 有权
    用于预测敏感性皮肤和测试套件的生物标记

    公开(公告)号:KR1020140123031A

    公开(公告)日:2014-10-21

    申请号:KR1020140124110

    申请日:2014-09-18

    CPC classification number: C12Q1/6844 C12Q1/6813

    Abstract: 민감성 피부에 대해서 특이적으로 유전자 발현량이 증가 또는 억제되는 바이오 마커가 개시된다. 상기 민감성 피부에 특이적인 바이오 마커를 이용하여 민감성 피부 진단 키트 및 자극감 완화제의 스크리닝 방법 등에 활용할 수 있다.

    Abstract translation: 公开了具有针对敏感皮肤特异性增加或降低的基因表达量的生物标志物。 敏感皮肤特异性的生物标志物用于敏感皮肤的诊断试剂盒和刺激物的筛选方法。 根据本发明的敏感性皮肤诊断用生物标志物,选自HLA-C,TCEA1,IGHA1,TFRC,S100A8,LOC652128,SERPINB13,EHF,FLJ10781,TP63,CDH1,TNFRSF19,GM2A, FKBP5,PI3,PSPH,HORMAD1,SPRR2G和ACTR2或由KBTBD10,TTN,ACTA1,MYBPC1,MB,MYOZ1,TPM1,CA3,CASQ1,ENO3,RBP4,GYG2,PPP1R1A,PYGM,G0S2,NEB,H19组成的组 ,LIPE,PLIN,H19,GPAM,FABP4,CIDEC,LPL,PCK1,ADIPOQ,PDE3B,ACVR1C,LPL,FABP4,DKFZP761N09121,TNMD,ATP6V1B1,C8orf22和CRISP3。

    모발 휴지기 또는 퇴행기 유도제를 포함하는 항암요법으로 인한 탈모증 예방 또는 개선용 조성물
    13.
    发明公开
    모발 휴지기 또는 퇴행기 유도제를 포함하는 항암요법으로 인한 탈모증 예방 또는 개선용 조성물 无效
    包含用于预防由癌症治疗诱发的ALOPECIA的CATAGEN或TELOGEN诱导剂的组合物和使用其预防ALOPECIA的方法

    公开(公告)号:KR1020130077778A

    公开(公告)日:2013-07-09

    申请号:KR1020120145380

    申请日:2012-12-13

    CPC classification number: A61K31/573

    Abstract: PURPOSE: A composition for preventing or treating alopecia caused by anticancer therapy and a method for preventing or treating alopecia are provided to reduce hair follicle dystrophy and the generation of side effects, to promote primary hair recovery, and to maximize therapeutic effects by preventing and/or suppressing alopecia caused by side effects when the composition is used with anticancer therapy. CONSTITUTION: A pharmaceutical composition for preventing or treating alopecia due to chemotherapy and radiotherapy for anticancer contains one or more telogen and/or catagen inducers. The telogen or catagen inducer is selected from a group consisted of epidermal growth factor (EGF), tumor necrosis factor (TGF-beta), dexamethasone, lipid peroxide, interferon-gamma, retinoic acid, and E2 (estrogen). A method for preventing or treating alopecia caused by chemotherapy and radiotherapy for anticancer comprises the step of topically administering the one or more telogen and/or catagen inducers on patient's scalp. A method for preventing or treating alopecia caused by chemotherapy and radiotherapy for anticancer is induction of hair cell growth cycle to telogen and/or catagen.

    Abstract translation: 目的:提供一种用于预防或治疗由抗癌治疗引起的脱发的组合物和预防或治疗脱发的方法,以减少毛囊营养不良和副作用的产生,促进初次毛发恢复,并通过预防和/ 或者当组合物与抗癌治疗一起使用时抑制由副作用引起的脱发。 构成:用于预防或治疗由于化学疗法和放射治疗的抗秃秃的药物组合物含有一种或多种前列腺素和/或诱导剂。 休止期或诱导诱导剂选自表皮生长因子(EGF),肿瘤坏死因子(TGF-β),地塞米松,脂质过氧化物,干扰素-γ,视黄酸和E2(雌激素)组成的组。 用于预防或治疗由化学疗法和放射治疗引起的脱发的抗癌方法包括在患者头皮上局部施用一种或多种休止期和/或吸收诱导剂的步骤。 用于预防或治疗由化学疗法和放射治疗引起的脱发的方法用于抗癌是诱导毛细胞生长循环到休止期和/或发作。

Patent Agency Ranking